Systemic Lupus Erythematosus Highlights 2017 - Designation, Collaboration, and Developments

Free Press Release DB | Press Release Date : Aug 31, 2017  Download

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development.

Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

Explore Report Sample at:

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Contact Person & Company



Vijay Kumar



P&s Market Research

Contact Numbers

Telephone No.



Fax No.


Handphone No.



Website 1


Go To PR Site

Website 2




PR Tags


Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Pipeline, Systemic Lupus Erythematosus Highlights, Systemic Lupus Erythematosus Pipeline Analysis,


347, 5th Ave. #1402

10016, New York City

United States

United States

Contact The Author

Contact Vijay Kumar

More Press Release From Author

MRI Compatible Patient Monitoring Systems Market is Increasing due to Increasing Prevalence of Chronic Diseases

Free Press Release DB :

Global MRI compatible patient monitoring systems market is growing, due to increasing installation of MRI devices. --> Read This Press Release !

By : Vijay, Kumar ( Jan 17, 2018 )
Category : Business Press Release | Country : United States Press Release

Prefilled Syringes Market - Global Industry Analysis, Size and Future Scope

Free Press Release DB :

Prefilled syringes market was valued at $3,905.1 million in 2014, and it is expected to grow with a CAGR of 12.9% till 2020. --> Read This Press Release !

By : Vijay, Kumar ( Jan 17, 2018 )
Category : Business Press Release | Country : United States Press Release

Hospital Infection Therapeutics Market Research Report, 2023

Free Press Release DB :

Hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections. --> Read This Press Release !

By : Vijay, Kumar ( Dec 7, 2017 )
Category : Healthcare Press Release | Country : United States Press Release

Read More Articles From Vijay Kumar


The author of the press releases are solely responsible for the content of their press releases. can't be held liable for the content posted by author. Please check the accuracy of the press release before using the press release. If necessary please contact the author. Thank you.

Report Abuse